



Uppsala January 19, 2017

PRESS RELEASE

Nomination committee appointed for Annual General Meeting 2017

A decision was taken on May 18, 2016 at the Annual General Meeting for AroCell AB (publ) that a nomination committee should be appointed and should consist of three members, comprised of the three largest shareholders on September 30, 2016, and the Chairman of the Board.

The nomination committee has been appointed accordingly, based on shareholdings on September 30, 2016:

Bernhard Tribukait, representing his own shareholdings
Staffan Eriksson, representing his own and related shareholdings
Jon Eiken, representing his own shareholdings
Erik Walldén, Chairman of the Board

Staffan Eriksson has been appointed as chairman of the nomination committee.

The nomination committee collectively represents approximately 10.2 percent of shareholder votes in AroCell AB (publ).

The Annual General Meeting will be held in Uppsala, Sweden on May 18, 2017.

Shareholders who wish to contact the nominating committee may do so by email to info@arocell.com or by letter to:

Nominating Committee
AroCell AB (publ)
Virdings allé 32B
754 50 UPPSALA

For additional information:

Jan Stålemark, CEO
AroCell AB (publ)
Tel: +46(0)706926206
info@arocell.com
www.arocell.com

This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through Jan Stålemark, at 11:10 CET on 19 January 2017.



Uppsala January 19, 2017

PRESS RELEASE

About AroCell

AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the speed of cell turnover. A tumor has high cell turnover (speed of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategy. The test may also be used for monitoring disease relapse. AroCell (AROC) is listed at Nasdaq First North and has about 2,600 shareholders. For more information, please see www.arocell.com. Redeye AB is AroCell:s Certified Adviser.